Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Renal Cell Carcinoma: early-phase trial registry
50 of 122 indexed Renal Cell Carcinoma trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #100 of 28,707 conditions by registered trial count.
122 US clinical trials · 50 currently recruiting · #100 of 28,707 conditions by registered trial count
Renal Cell Carcinoma: 122 US clinical trials tracked, 50 recruiting.
Renal Cell Carcinoma is the subject of 122 registered US clinical trials on ClinicalTrials.gov, 50 of them currently open to new participants. 10 are in Phase 3-4 (later-stage) and 90 in Phase 1-2 (earlier-stage). The most active sponsor is M.D. Anderson Cancer Center, running 7 of these trials.
Enrollment posture brief
Registry condition renal-cell-carcinoma
OPEN 50 | RECR 41% | LATE 10 | EARLY 90 | RANK #100 | SPON 7
Volume-matched condition peers
Nearest open-share peer: Ovarian Neoplasms (41% recruiting · 39 trials)
Renal Cell Carcinoma lists 50 open slots (41% of 122 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Renal Cell Carcinoma on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Renal Cell Carcinoma is recruiting above its size-band peers.
50 of 122 indexed trials (41%) are open to enrollment, against a 37.1% average across 139 conditions with 100+ trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
Sponsorship of Renal Cell Carcinoma trials is spread across many organizations.
M.D. Anderson Cancer Center accounts for 7 of 122 trials (5.7%). 87 distinct sponsors appear on at least one study for this condition label.
-
Typical Renal Cell Carcinoma enrolment sits around 80 participants.
Median target enrolment is 80 among the 122 trials that report a genuine target (sentinel values excluded). 69 of those (56.6%) plan for fewer than 100 participants.
-
Renal Cell Carcinoma research is mostly interventional.
110 interventional and 12 observational studies make up this index (90.2% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
122 total, page 1 of 3
Von Hippel-Lindau (VHL): Clinical Manifestations, Diagnosis, Management and Molecular Bases of Inherited Renal and Other Urologic Malignant Disorders
National Cancer Institute (NCI)
NCT00001238
A Multicenter Cancer Biospecimen Collection Study
Cofactor Genomics
NCT04510129
Improving Nutrition and Physical Activity for Cancer Survivors (Tools To Be Fit)
University of California, San Francisco
NCT05056077
The Gut Microbiome and Immune Checkpoint Inhibitor Therapy in Solid Tumors
VastBiome
NCT05037825
An Investigation of Kidney and Urothelial Tumor Metabolism in Patients Undergoing Surgical Resection and/or Biopsy
University of Texas Southwestern Medical Center
NCT04623502
Frequency and Clinical Phenotype of BAP1 Hereditary Predisposition Syndrome
Mohamed Abdel-Rahman
NCT04792463
Patient Preference for Subcutaneous vs. Intravenous Immune Therapy
Diwakar Davar
NCT07223424
A Study of Pazopanib With or Without Abexinostat in Patients With Locally Advanced or Metastatic Renal Cell Carcinoma (RENAVIV)
Xynomic Pharmaceuticals
NCT03592472
Phase 1a and Phase 2 Study for Safety, Preliminary Efficacy, PK and PD of ST-067
Simcha IL-18
NCT04787042
Comparing Single vs Multiple Dose Radiation for Cancer Patients With Brain Metastasis and Receiving Immunotherapy
Wake Forest University Health Sciences
NCT05703269
Contrast-Enhanced Ultrasound Imaging for Diagnosing Recurrent Renal Cell Carcinoma (RCC) Post Ablation
john eisenbrey
NCT05641935
A Phase I Clinical Study to Evaluate the PK Profile, Efficacy, Safety and Immunogenicity of HLX17 vs. Keytruda® in Multiple Resected Solid Tumors
Shanghai Henlius Biotech
NCT07160335
Locally Ablative TherapY in Oligo-ProgressiVe GEnitourinary TumoRs (LAYOVER)
University of California, Davis
NCT06101290
Substudy 03C: A Study of Combination Therapies in Participants With Renal Cell Carcinoma With Recurrent Disease During or After Anti-PD-(L)1 Therapy (MK-3475-03C/KEYMAKER-U03)
Merck Sharp & Dohme
NCT07049926
Study of JANX008 in Subjects With Advanced or Metastatic Solid Tumor Malignancies
Janux Therapeutics
NCT05783622
A Study of Oral 7HP349 (Alintegimod) in Combination With Ipilimumab Followed by Nivolumab Monotherapy
7 Hills Pharma
NCT06362369
A First-in-Human Study of BMS-986506 in Participants With Advanced Clear Cell Renal Cell Carcinoma (ccRCC)
Bristol-Myers Squibb
NCT07195682
A Study to Evaluate Safety, Efficacy, and Pharmacokinetics in Participants With Advanced Solid Tumors
Eutilex
NCT04903873
Molecular Residual Disease (MRD) Guided Adjuvant ThErapy in Renal Cell Carcinoma (RCC)
University of Alabama at Birmingham
NCT06005818
Safety, PK and Efficacy of QXL138AM in Patients With Solid Tumors and Multiple Myeloma
Nammi Therapeutics
NCT06582017
PET/MR for Characterization of Renal Masses (RMs)
University of Texas Southwestern Medical Center
NCT06076538
A Study of HC-7366 in Combination With Belzutifan (WELIREG™) in Patients With Renal Cell Carcinoma
HiberCell
NCT06234605
IDOV-Immune for Advanced Solid Tumors
ViroMissile
NCT06910657
A Phase 1, Dose-escalation Study of [225Ac]-FPI-2068 in Adult Patients With Advanced Solid Tumours
AstraZeneca
NCT06147037
Testing of Bevacizumab, Erlotinib, and Atezolizumab in Combination for Advanced-Stage Kidney Cancer
National Cancer Institute (NCI)
NCT04981509
A Study to Investigate Safety of AZD6750 in Adult Participants With Select Advanced or Metastatic Solid Tumors
AstraZeneca
NCT07115043
Study of DCC-2812 in Participants With Advanced Genitourinary Cancers
Deciphera Pharmaceuticals
NCT06966024
A Study of VET3-TGI in Patients With Solid Tumors
KaliVir Immunotherapeutics
NCT06444815
89Zr-DFO-Atezolizumab ImmunoPET/CT in Patients With Locally Advanced or Metastatic Renal Cell Carcinoma
James Brugarolas
NCT04006522
Phase 2 Study of Combination Tivozanib and Nivolumab in Advanced Non-Clear Cell Renal Cell Carcinoma
M.D. Anderson Cancer Center
NCT06053658
CYTO Reductive Surgery in Kidney Cancer Plus Immunotherapy and Targeted Kinase Inhibition
Mark Stein
NCT04322955
A Phase II Study of Cyberknife Radiosurgery for Renal Cell Carcinoma
Beth Israel Deaconess Medical Center
NCT01890590
Retifanlimab and Ruxolitinib In Solid Malignancies
University of California, San Diego
NCT07219576
[18F]PT2385 PET/CT in Patients With Renal Cell Carcinoma
Orhan Kemal Oz
NCT04989959
Pre-NEOSHIFT-RCC: Neoadjuvant HIF-Inhibitor Immunotherapy in RCC
Dana-Farber Cancer Institute
NCT07397611
Positron Emission Tomography (PET) Guided Stereotactic Body Radiation Therapy for the Treatment of Oligoprogressive Non-small Cell Lung Cancer, Melanoma, and Renal Cell Carcinoma
City of Hope Medical Center
NCT05830058
Open-Label Phase 1/2 Study of NEO-811 in Subjects With Locally Advanced or Metastatic Non-Resectable Clear Cell Renal Cell Carcinoma
Neomorph
NCT07300241
Neoadjuvant Lenvatinib and Pembrolizumab for IVC Tumor Thrombus
University of Texas Southwestern Medical Center
NCT05319015
Neoadjuvant Pembrolizumab and Lenvatinib for Renal Cell Carcinoma
Abramson Cancer Center at Penn Medicine
NCT05733715
Trial Of Stereotactic Body Radiation Therapy (SBRT) for Oligoprogression on Immune Checkpoint Inhibitors (ICI) in Metastatic Renal Cell Carcinoma
Yale University
NCT04974671
Rapid Sequencing of Approved Therapies in Patients with Metastatic or Unresectable Clear Cell Renal Cell Carcinoma
Icahn School of Medicine at Mount Sinai
NCT05188118
Study of Olaparib in Metastatic Renal Cell Carcinoma Patients With DNA Repair Gene Mutations
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
NCT03786796
A Phase II Study of Nivolumab With Ipilimumab and Cabozantinib in Patients With Untreated Renal Cell Carcinoma Brain Metastases
M.D. Anderson Cancer Center
NCT05048212
Stereotactic Body Proton Therapy for Treatment of Primary Renal Cell Carcinoma
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
NCT06376669
Sequential Treatment of Cabozantinib for Advanced Renal Cell Carcinoma (RCC)
University of Texas Southwestern Medical Center
NCT05931393
Neoadjuvant Pembrolizumab and Axitinib in Renal Cell Carcinoma With Inferior Vena Cava Tumor Thrombus
University of Colorado, Denver
NCT05969496
Analysis of Primary and Metastatic Tumors in Patients With Renal Cell Carcinoma and Urothelial Carcinoma
Fox Chase Cancer Center
NCT03291028
Memory-like Natural Killer (NK) Cell Therapy in Patients With Renal Cell Carcinoma or Urothelial Carcinoma
Dana-Farber Cancer Institute
NCT06318871
A Study of Cemiplimab and Fianlimab in People With Clear Cell Renal Cell Carcinoma
Memorial Sloan Kettering Cancer Center
NCT06699602
Transplantation of Reconstructed Renal Allografts Following Ex-Vivo Partial Nephrectomy
Case Comprehensive Cancer Center
NCT05725421
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 51 |
| Phase 2 | 39 |
| Phase 3 | 10 |
Top Sponsors
Named interventions
Most-linked intervention names on Renal Cell Carcinoma records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Renal Cell Carcinoma trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Renal Cell Carcinoma page
122 registered trials, 50 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 50 Renal Cell Carcinoma trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- M.D. Anderson Cancer Center sponsors the most Renal Cell Carcinoma trials on record, review their full trial history before evaluating a specific study. See M.D. Anderson Cancer Center's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Renal Cell Carcinoma condition card totals 122 registered trials; most-linked intervention Nivolumab; top US site state California. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.